Schear Investment Advisers LLC Sells 2,189 Shares of Novo Nordisk A/S (NYSE:NVO)

Schear Investment Advisers LLC cut its position in Novo Nordisk A/S (NYSE:NVO) by 33.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,274 shares of the company’s stock after selling 2,189 shares during the quarter. Schear Investment Advisers LLC’s holdings in Novo Nordisk A/S were worth $368,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in NVO. Novare Capital Management LLC boosted its stake in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock valued at $325,000 after purchasing an additional 85 shares in the last quarter. Fiduciary Alliance LLC boosted its position in Novo Nordisk A/S by 7.6% in the third quarter. Fiduciary Alliance LLC now owns 7,278 shares of the company’s stock valued at $867,000 after buying an additional 511 shares in the last quarter. Wesbanco Bank Inc. grew its stake in shares of Novo Nordisk A/S by 35.3% during the third quarter. Wesbanco Bank Inc. now owns 83,892 shares of the company’s stock worth $9,989,000 after buying an additional 21,904 shares during the last quarter. Creative Planning increased its holdings in shares of Novo Nordisk A/S by 4.7% during the third quarter. Creative Planning now owns 294,799 shares of the company’s stock worth $35,102,000 after buying an additional 13,203 shares in the last quarter. Finally, Iams Wealth Management LLC lifted its stake in shares of Novo Nordisk A/S by 7.2% in the 3rd quarter. Iams Wealth Management LLC now owns 17,003 shares of the company’s stock valued at $2,025,000 after acquiring an additional 1,144 shares during the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $83.78 on Wednesday. The stock has a market cap of $375.95 billion, a P/E ratio of 25.46, a P/E/G ratio of 0.96 and a beta of 0.45. The business’s fifty day moving average is $90.96 and its 200 day moving average is $110.91. The company has a quick ratio of 0.75, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio is presently 47.72%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on NVO shares. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.